drugset / Trial / NCT05846568
Study to Evaluate GR1801's Efficacy and Safety
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The goal of this clinical trial is to compare the efficacy and safety of GR1801 injection with Human Rabies Immunoglobulin(HRIG) in patients with WHO Category 3 rabies exposure. Patients will receive GR1801 injection or HRIG. Each group will receive rabies vaccine as the WHO Essen regime after Study Drug.
Timeline
- Start
- 2022-10-21
- Primary completion
- 2023-09-06
- Completion
- 2024-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GR1801 | Monoclonal antibody | 0.05 mg/kg | Other |
| Comparator | Human Rabies Immunoglobulin | Protein / enzyme biologic | 20 iu/kg | Other |
| Background | Rabies vaccine | Vaccine | 2.5 iu | Intramuscular |